-
Oral Cholesterol-Lowering Peptide Wins Approval After Decade-Long Journey
A new oral peptide therapy designed to help manage cholesterol has received regulatory approval, marking the culmination of ten years of research and development. The milestone offers patients a needle-free option for cardiovascular health support.
-
Ascletis Advances Two Novel Obesity Peptide Candidates with FDA IND Submissions
Ascletis has submitted two Investigational New Drug applications to the FDA for once-monthly injectable peptide therapies targeting obesity, including a novel amylin receptor agonist and a combination formulation with a GLP-1R/GIPR agonist.
-
FDA Advisory Panel Vote Signals Broader Access to Popular Peptides
A recent FDA panel vote suggests millions of Americans could soon see easier access to popular peptide compounds, marking a potential shift in how these therapies are regulated.
-
Nuritas’ PeptiSleep Peptide Shows Promise for Better Sleep and Heart Rate Variability
Nuritas’ PeptiSleep, a bioactive peptide developed using AI-driven discovery methods, has demonstrated improvements in sleep quality and heart rate variability (HRV) in recent findings, offering a promising new avenue for natural sleep support.
-
Silk-Derived Peptide Platform Powers New FDA-Cleared Therapy for Atopic Dermatitis
Evolved By Nature’s peptide-based technology platform has been incorporated into a newly FDA-cleared prescription therapy designed to help manage atopic dermatitis. The milestone highlights growing momentum for peptide science in dermatological care.
-
FDA Advisory Committee Votes to Expand Access to Peptide Therapies
An FDA advisory committee has voted in favor of broadening access to peptide-based treatments, a move that could open the door to wider clinical use in the future.
-
Promising ‘Triple-Agonist’ Weight Loss Peptide Reaching Some Patients Ahead of Full Approval
A next-generation weight-loss therapy that targets three key metabolic hormones is showing strong results in trials, and select patients may gain earlier access through expanded-access pathways ahead of full FDA approval.
-
Retatrutide: What Emerging Research Suggests About This Promising Investigational Peptide
Retatrutide, a triple-hormone receptor agonist still in clinical trials, is generating excitement for its potential to support significant weight loss and metabolic health improvements.
-
FDA Advisory Committee Gives Favorable Nod to Six Peptides, Signaling Progress Toward Broader Access
An FDA advisory committee has voted in favor of six peptides, marking an encouraging step in the ongoing regulatory process that could shape their future availability. The decision reflects growing scientific engagement with peptide therapies.
-
FDA Advisory Panel Signals Support for Wider Access to BPC-157 and TB-500
A majority of FDA advisers have voiced support for making peptides like BPC-157 and TB-500 available in the U.S., marking a potentially significant step toward expanded legal access.